Analysts Set Expectations for CRNX FY2025 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Crinetics Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($4.30) per share for the year. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share.

CRNX has been the topic of several other reports. Citigroup upped their target price on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $87.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. Finally, Jefferies Financial Group raised shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Wednesday. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $72.64.

Crinetics Pharmaceuticals Trading Down 0.3 %

NASDAQ CRNX opened at $38.65 on Wednesday. Crinetics Pharmaceuticals has a 1-year low of $35.51 and a 1-year high of $62.53. The firm’s fifty day simple moving average is $51.60 and its 200-day simple moving average is $52.87. The company has a market capitalization of $3.58 billion, a PE ratio of -10.36 and a beta of 0.60.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.05). During the same quarter in the previous year, the firm earned ($1.01) EPS.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, COO Jeff E. Knight sold 501 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.52, for a total transaction of $28,316.52. Following the completion of the transaction, the chief operating officer now directly owns 51,653 shares in the company, valued at $2,919,427.56. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Values First Advisors Inc. bought a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth about $84,000. Allspring Global Investments Holdings LLC acquired a new stake in Crinetics Pharmaceuticals during the third quarter worth about $91,000. KBC Group NV lifted its position in shares of Crinetics Pharmaceuticals by 22.8% in the 3rd quarter. KBC Group NV now owns 2,193 shares of the company’s stock worth $112,000 after acquiring an additional 407 shares during the period. Amalgamated Bank grew its holdings in shares of Crinetics Pharmaceuticals by 20.8% during the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock worth $121,000 after purchasing an additional 464 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Crinetics Pharmaceuticals by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 2,806 shares of the company’s stock worth $143,000 after buying an additional 1,008 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.